However, once-weekly dulaglutide would not impact UACR or even the annual change of eGFR, nor achieved it showcase any adverse effects regarding customers.
Dulaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 5 era and has a recommended quantity of once-weekly (8-10). Randomized stage II and III clinical studies have reported that once-weekly dulaglutide reveals no differences in regards to safety and efficiency between people with typical renal purpose and clients with reduced renal function (10). Hence, it entails no dose modification for use in people with renal impairment. Moreover, a phase III clinical learn stated that once-weekly dulaglutide substantially lower HbA1c degrees in type 2 diabetes mellitus people with typical renal function versus once-daily liraglutide after 52 weeks (11). In our learn, once-weekly dulaglutide somewhat paid off HbA1c grade without any adverse effects in clients with advanced-stage diabetic nephropathy after switching from once-daily liraglutide. These outcomes claim that once-weekly dulaglutide is much more advantageous for glycemic controls compared to once-daily liraglutide, also it can be utilized properly in patients with advanced-stage diabetic nephropathy.
Research has reported that GLP-1 receptor agonists have nephroprotective issues, that are in addition to the glucose-lowering impact (14, 15). Liraglutide is reported to reduce proteinuria and attenuate the progression of renal dysfunction (16-18). Lately, integrated information from phase II and III trials indicated that dulaglutide in addition decreased urinary albumin excretion in clients with diabetes and slight renal impairment (12). In our study, we couldn’t note these nephroprotective impact after 
There are various limitations within our study. First, it is a retrospective observational learn, which might be subjected to significant collection prejudice. Next, this research is founded on a small amount of clients from just one middle, which limitations the possibility of generalizing our conclusions. Therefore, extensive, double-blind studies are required to con??A¬??rm the ef??A¬??cacy of dulaglutide on glycemic controls as well as on nephroprotection in people with advanced-stage diabetic nephropathy.
To conclude, once-weekly dulaglutide increased glycemic regulation without revealing any undesireable effects in customers with advanced-stage diabetic nephropathy after modifying from once-daily liraglutide. These outcomes suggest that once-weekly dulaglutide is more beneficial for glycemic regulation when compared to once-daily liraglutide also it could possibly be used properly in people with advanced-stage diabetic nephropathy.
Recommendations
Ghaderian SB, Hayati F, Shayanpour S, Beladi Mousavi SS. Diabetes and end-stage renal condition; a review post on brand new principles. J Renal Inj Prev. 2015; 4(2) : 28 -33 [DOI][PubMed]
Palsson R, Patel UD. Heart issues of diabetic kidney condition. Adv Chronic Kidney Dis. 2014; 21(3) : 273 -80 [DOI][PubMed]
Wong milligrams, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-lasting Great Things About Intensive Sugar Controls for Combating End-Stage Kidney Disorder: ADVANCE-ON. Diabetes Worry. 2016; 39(5) : 694 -700 [DOI][PubMed]
Footnote
Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJGL, McCarren M, et al. VADT Investigators. Follow-up of glycemic regulation and cardiovascular outcomes in diabetes. N Engl J Med . 2015; 372 : 2197 -206
Trujillo JM, Nuffer W. GLP-1 receptor agonists for diabetes mellitus: recent developments and rising representatives. Pharmacotherapy. 2014; 34(11) : 1174 -86 [DOI][PubMed]
Kim W, Egan JM. The role of incretins in sugar homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4) : 470 -512 [DOI][PubMed]